Back grey_arrow_rt.gif
 
Archived NATAP Articles from November 2003
 
null.gif
 
 
  1. Ultrasound Assisted Liposuction Reduces Buffalo Hump - (11/30/03)
     
  2. Prolonged Treatment Interruption after Immunologic Response to Highly Active Antiretroviral Therapy - (11/30/03)
     
  3. Pretreatment Intrahepatic CD8+ Cell Count Correlates with Virological Response to Antiviral Therapy in Chronic Hepatitis C Virus Infection - (11/30/03)
     
  4. Anemia in the Treatment of Hepatitis C Virus Infection - (11/30/03)
     
  5. New NIH Liver Disease Research Branch: Action Plan For Liver Disease Research - (11/30/03)
     
  6. New study shows overall increases in HIV diagnoses: African Americans, Latinos, Gay and Bisexual Men most affected; Impact of HIV/AIDS on Select Populations reported below - (11/30/03)
     
  7. Hepatitis A Outbreak Associated with Green Onions at a Restaurant --- Monaca, Pennsylvania, 2003 - (11/30/03)
     
  8. Increases in HIV Diagnoses --- 29 States, 1999-2002 - (11/30/03)
     
  9. H.I.V. Infections Continue Rise, Study Says - (11/30/03)
     
  10. On World AIDS Day Dr Fauci from the NIH Calls AIDS a Plague - (11/30/03)
     
  11. Sampling variability of liver fibrosis in chronic hepatitis C - (11/30/03)
     
  12. CCR5 and Outcome of HCV Infection - (11/30/03)
     
  13. HIV Sexual Secrecy is Deadly: don't tell - (11/30/03)
     
  14. Sixty Percent of Heterosexuals and One-third of Gays Have Never Been Tested for HIV - (11/30/03)
     
  15. Man Convicted of Using HIV as a Threat Loses Appeal - (11/30/03)
     
  16. California Slashes HIV Funding Program - (11/30/03)
     
  17. AIDS Drugs Increase Risk of Heart Attack; But Study Indicates Benefit of Therapy Exceeds Threat - (11/30/03)
     
  18. HIV Infection Linked to Brain Damage - (11/30/03)
     
  19. U.S. Syphilis Rates Climb for the Second Year: LA, Georgia, Chicago - (11/30/03)
     
  20. Transjugular Liver Core Biopsy: Indications, Results, and Complications - (11/30/03)
     
  21. Interruptions & Drug Resistance - (11/30/03)
     
  22. MULTI-CENTER EVALUATION OF THE VERSANT HBV DNA 3.0 ASSAY: ASSESSMENT OF ANALYTICAL AND CLINICAL PERFORMANCE - (11/30/03)
     
  23. India Plans Free AIDS Therapy - (11/30/03)
     
  24. Novel agents show promise as anti-HIV compounds - (11/30/03)
     
  25. Soap and water inactivate HIV - (11/30/03)
     
  26. Report: AIDS discrimination in U.S. is widespread - (11/30/03)
     
  27. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients - (11/30/03)
     
  28. Treatment of pre- and post-liver transplantation HBV infection: Should we aim at combination therapy? - (11/30/03)
     
  29. EACS - Atazanavir Maintained Patient Utility and Improved Quality of Life, Comparing Favorably to LPV/RTV: 24-Week Data from BMS 043 - (11/30/03)
     
  30. EACS - Virologic Determinants of 24-Week Efficacy of Atazanavir With or Without Ritonavir in Patients with Prior Failure of a Protease Inhibitor - (11/30/03)
     
  31. EACS - Prevalence of HIV and Hepatitis B and C Among Drug Addicts in the Holy City of Amritsar, India - (11/30/03)
     
  32. EACS - FUZEON: EFFICACY OF ENFUVIRTIDE (Fuzeon) IN SUBGROUPS OF PATIENTS THROUGH 48 WEEKS OF THERAPY IN THE TORO TRIALS - (11/30/03)
     
  33. EACS - FUZEON: PATIENT ACCEPTANCE WITH SELF-INJECTION OF ENFUVIRTIDE (Fuzeon) FOR HIV OVER 48 WEEKS OF TREATMENT - (11/30/03)
     
  34. EACS - FUZEON: IMPACT OF ENFUVIRTIDE (Fuzeon) ON HEALTH-RELATED QUALITY OF LIFE AT 48 WEEKS - (11/30/03)
     
  35. EACS - Atazanavir Maintained Patient Utility and Improved Quality of Life, Comparing Favorably to LPV/RTV: 24-Week Data from BMS 043 - (11/30/03)
     
  36. EACS - 2 Year Long Term Safety Profile of Tenofovir DF (TDF) in Treatment-Experienced Patients from Randomized, Double-Blind, Placebo-Controlled Clinical Trials - (11/30/03)
     
  37. Gilead Announces Preliminary Results from 48-Week Phase III Study of Emtricitabine in Patients with Chronic Hepatitis B - (11/26/03)
     
  38. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis - (11/26/03)
     
  39. NIDA - Report 1 HCV & Substance Abuse Conference - (11/24/03)
     
  40. EACS - Once Daily Saquinavir/r: pharmacokinetcs (drug levels) and bioequivalence of new 500 mg Invirase tablet - (11/24/03)
     
  41. How bad is HAART for the HEART? - (11/24/03)
     
  42. African AIDS Crisis Program From Bristol-Myers Squibb - (11/24/03)
     
  43. Hepatitis C Virus and Human Immunodeficiency Virus Dynamics during HCV Treatment in HCV/HIV Coinfection - (11/24/03)
     
  44. Higher Baseline Levels of Plasma Human Immunodeficiency Virus Type 1 RNA Are Associated with Increased Mortality after Initiation of Triple-Drug Antiretroviral Therapy - (11/24/03)
     
  45. Transplantation for Patients Infected with HIV: No longer Experimental but not yet routine (editorial) - (11/24/03)
     
  46. Survival of HIV-Infected Liver Transplant Recipients - (11/24/03)
     
  47. EACS - EPIDEMIOLOGY OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN AN ETHNICALLY DIVERSE HIV INFECTED COHORT - (11/21/03)
     
  48. EACS - MATERNAL TOLERABILITY OF ANTIRETROVIRAL THERAPY IN PREVENTING VERTICAL TRANSMISSION OF HIV-1 - (11/21/03)
     
  49. EACS - DRAMATIC REDUCTION, BUT NO ELIMINATION, OF PERINATAL HIV TRANSMISSION - (11/21/03)
     
  50. EACS - Atazanavir is Associated with Better Patient Adherence: Long-Term Follow-Up Data from BMS 041 and 044 Studies - (11/21/03)
     
  51. Combination Antiretroviral Therapy and the Risk of Myocardial Infarction - (11/20/03)
     
  52. EACS - TREATMENT INTERRUPTION IN PATIENTS WITH MULTIPLE FAILURES TO ARV THERAPY: CAN THE CONTROVERSY BE SOLVED? - (11/20/03)
     
  53. EACS - FAVOURABLE INCREASES IN HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) CONCENTRATIONS IN CHRONIC HIV-INFECTED THERAPY NA¤VE SUBJECTS RECEIVING 908/R QD IN THE SOLO STUDY - (11/20/03)
     
  54. EACS - Hepatitis B in the Eurosida Cohort: prevalence, impact on mortality, AIDS progression, and response to HAART - (11/20/03)
     
  55. EACS - Patient Acceptance with Self-Injection of Fuzeon (Enfuvertide) for HIV Over 48 Weeks of Treatment - (11/20/03)
     
  56. HCV Nucleoside Analogue Studied in Chronically Infected Patients; new HIV Microbicide - (11/19/03)
     
  57. EACS - Assisted Medical Procreation for HIV+ and HCV+ Couples & Pregnancy - (11/19/03)
     
  58. EACS - Increase in Mitochondrial DNA in PBMCs Following switch from d4T to Tenofovir - (11/19/03)
     
  59. EACS - Atazanavir Once Daily Protease Inhibitor Adherence Evaluated - (11/19/03)
     
  60. EACS - Lopinavir/r (Kaletra) As Sole Therapy for HIV - (11/19/03)
     
  61. EACS - Trizivir in Treatment-Naives: can it still be considered as a first line treatment option? - Graeme Moyle, MD, Chelsea & Westminster Hospital, London, UK - (11/18/03)
     
  62. EACS - Kaletra resistance: hard to find in first line and second line use - (11/18/03)
     
  63. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men - (11/17/03)
     
  64. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA - (11/17/03)
     
  65. Living with HIV Therapy: Effects of HIV Infection and Treatment on Physical Appearance and Body Image - (11/17/03)
     
  66. EACS - Switching from PI to Trizivir or Nevirapine Due to Lipid Abnormalities - (11/17/03)
     
  67. NIDA - Report 4 from the NIDA HCV & Substance Abuse Conference - (11/17/03)
     
  68. NIDA - Day 3, NIDA HCV & Substance Abuse Conference - (11/17/03)
     
  69. Hyperbilirubinemia and HIV Antiretroviral Treatment - (11/13/03)
     
  70. EACS - Hypophosphataemia in Patients Taking Tenofovir - (11/13/03)
     
  71. AASLD - Treating HCV with Normal ALT with Pegasys plus Ribavirin - (11/10/03)
     
  72. AASLD - DELAYED RECOVERY OF PEGYLATED INTERFERON AND RIBAVIRIN INDUCED ANEMIA - (11/10/03)
     
  73. AASLD - Albuferon: new HCV drug in early study - (11/10/03)
     
  74. AASLD - Continuous Pump Infusion of Consensus Interferon in Non-respondersto HCV Therapy: pilot study - (11/10/03)
     
  75. EACS - 4 Drug HAART Regimen vs 3 Drug Regimen: Combivir vs Trizivir plus SQV/r (1000/100 mg bid) - (11/10/03)
     
  76. EACS - IL-2 effectively increases CD4 count in persons with low CD4 nadir - (11/10/03)
     
  77. Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes: A Randomized Controlled Trial - (11/10/03)
     
  78. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse - (11/10/03)
     
  79. Synthetic Liver - (11/10/03)
     
  80. Ribavirin Substitute: Viramidine entering phase III - (11/10/03)
     
  81. EACS - Heart Disease & Hepatotoxicity Among Leading Causes for Hospitalizations - (11/06/03)
     
  82. EACS - Tipranavir Report from 2003 European AIDS Conference - (11/06/03)
     
  83. AASLD - Rofecoxib (Vioxx) Prevents Reduction in Platelets During Pegasys Therapy for HCV: short term pilot study - (11/05/03)
     
  84. AASLD - LdT: new drug for HBV, phase II study results - (11/05/03)
     
  85. AASLD - Effects of Lamivudine on Disease Progression and Development of Liver Cancer in Advanced Chronic Hepatitis B: a prospective double-blind placebo controlled clinical trial - (11/05/03)
     
  86. EACS - Once Daily Kaletra; 24 week study results - (11/05/03)
     
  87. EACS - 5-Year Results of Lopinavir/ritonavir (LPV/r)-Based Therapy in Antiretroviral-Naïve HIV-Infected Patients - (11/05/03)
     
  88. HIV viral load in Blood may not predict HIV shedding in vaginal secretions - (11/05/03)
     
  89. UK man jailed for infecting lovers with HIV - (11/05/03)
     
  90. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C - (11/04/03)
     
  91. Virus and Host Factors in HIV Pathogenesis - (11/04/03)
     
  92. HIV Immunopathogenesis and Correlates of Protection: treatment during acute HIV - (11/04/03)
     
  93. AASLD - Study Urges Doctors to Screen for Hepatitis - (11/04/03)
     
  94. AASLD - Hepatitis C in Elderly Goes Undetected and Is More Severe - (11/04/03)
     
  95. AASLD - Long Term (96 Weeks) Adefovir in HBeAg Negative Chronic Hepatitis B Results in Significant Virological, Biochemical, and Histologic Improvement - (11/04/03)
     
  96. AASLD - LONG-TERM FOLLOW-UP OF CHRONIC HEPATITIS C PATIENTS - RESPONSE TO THERAPY AND INCIDENCE OF LIVER-RELATED COMPLICATIONS - (11/04/03)
     
  97. AASLD - Effects of Lamivudine on Disease Progression and Development of Liver Cancer in Advanced Chronic Hepatitis B: a prospective double-blind placebo controlled clinical trial - (11/04/03)
     
  98. EACS - Is Kaletra a once daily protease inhibitor? - Graeme Moyle, MD - (11/04/03)
     
  99. EACS - Resistance: Atazanavir, Atazanavir/rtv, and Kaletra--studies 043, 045 - Graeme Moyle, MD - (11/04/03)
     
  100. EACS - HCV Sexual Transmission --MSM & Heterosexual - (11/04/03)
     
  101. EACS - Kaletra Drug levels in HCV/HIV Coinfection - (11/04/03)